Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Avodes - biotechnological menstrual product for Candidiasis prevention

Project description

Biotechnological product for candidiasis prevention

More than 370 million women globally have a silent torturer - vulvovaginal candidiasis. It affects 75 % women at some point in their lives, and can be recurrent. If left untreated, it can lead to infertility, pre-term birth, suppression of the immune system, pelvic inflammatory disease, ectopic pregnancy, menstrual disorders and miscarriage. Avodes has developed an innovative medical device - biotechnological solution impregnated sponge made of completely natural, biodegradable materials. It preserves Lactobacilli of vaginal microflora at the same time selectively inhibiting growth of pathogens during the most vulnerable period of menstruation. Fluctuating hormones and the microbiota disbalance cause yeast infection reoccurrence. Avodes effectively disrupts the vicious cycle of 'microbiota disbalance' and offers a solution that protects women’s health and the environment.

Objective

372 million women globally have a silent torturer - recurrent vulvovaginal candidiasis (VVC) , which affects 3 out of 4 women at some point in their lives. Despite therapeutic advances, VVC remains a common problem worldwide, affecting all strata of society and being the second largest gynaecological infection. If it is left untreated, many complications have been appointed as its consequence, such as infertility, subsequent preterm delivery, suppression of the immune system, pelvic inflammatory disease, ectopic pregnancy, pelvic abscess, menstrual disorders and miscarriage.
Avodes has developed an innovative medical device for menstruation - a patented anatomically shaped “moist sponge” made of completely natural, biodegradable materials (biodegradable within 1 month). It protects innate defence mechanisms of vaginal microflora during most vulnerable period – menstruation. Studies have shown, that fluctuating hormones and the resulting imbalance of vaginal flora cause an increased risk of a yeast infection every month. Unique Avodes biotechnological solution preserves women’s natural vaginal microbiota in the same time selectively inhibiting growth of pathogenic microorganisms. It reduces risk of vulvovaginal candidiasis (VVC) by 85 % thus effectively preventing the disease. Avodes is the only medical product designed to prevent infection, rather than deal with the consequences. Avodes effectively disrupts the vicious cycle of ”microbiota disbalance –> infection –> antibiotic/fungicidal treatment–> microbiota disbalance” and offers break-through solution which protects women’s health and the environment.
Women Tech EU programme would support company in upgrading the business model, business and marketing plan, market validation and would help to find partners (clinical, manufacturing and commercial) as well as to prepare funding strategy. Successful project implementation will provide much needed tailwind to our company to bring the product to the market.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

You need to log in or register to use this function

Coordinator

UAB AVODES
Net EU contribution
€ 75 000,00
Address
VASARIO 16-OSIOS G. 6-21
LT-44250 Kaunas
Lithuania

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Lietuva Vidurio ir vakarų Lietuvos regionas Kauno apskritis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data